Scanning and combinatorial library services – Save 20% with code TRY-BXPLIB-20

Neoantigen synthesis

Precision medicine without contaminants or immunogenicity

Neoantigen synthesis

Neoantigens — or tumor mutated specific antigens (TMSA) — are a major tumor rejection antigen, allowing tumors to activate the immune system and induce an efficient anti-tumor response.

As personalized medicine for cancer therapeutics ramps up and becomes more feasible and affordable, individual patient neoantigen development is increasingly important.

Identification of these neoantigens has been greatly improved with recent advancements in deep sequencing and bioinformatics technologies. Gene synthesis then allows for these predicted neoantigens to be synthesized and tested for T cell reactivity, differentiating true immunogenic neoepitopes from putative ones.

Neoantigen Applications

Accelerating personalized neoantigen synthesis

Since patients’ mutated antigens are largely unique to the individual, speed is one of the most important variables for identifying and verifying true neoantigens for induction of the T cell-mediated immune response. The BioXp™ 3200 system's high-throughput gene synthesis and flexible cloning into a variety of vectors allow for quick screening and development of the best personalized cancer treatment.

Learn more

Questions? Suggestions? Need additional info?

The expertise of our scientists, engineers, and supporting teams is always available. Or call us: 858.228.4115

By clicking Submit, you agree that Codex DNA may use this information to contact you about our programs, products, or services. You may opt out at any time.

Your personal data is handled according to our privacy policy. In addition, if you are located within a distributor territory, you may be contacted directly by them. We never sell your data to anyone.